MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2025 International Congress
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Substantia nigra"

  • 2017 International Congress

    Substantia nigra area evaluated by neuromelanin-sensitive MRI as an imaging biomarker of disease progression in Parkinson’s disease

    M. Fabbri, S. Reimão, M. Carbalho, R. Nunes, D. Abreu, L. Guedes, R. Bouça, P. Lobo, C. Godinho, M. Coelho, N. Gonçalves, M. Rosa, A. Antonini, J. Ferreira (Lisbon, Portugal)

    Objective: to investigate the pattern of substantia nigra - neuromelanin (SN-NM) area loss and contrast ratio (CR) intensity changes in late-stage Parkinson’s disease (LSPD) patients,…
  • 2017 International Congress

    High-Pass Filtered Phase MR Imaging to Detect Longitudinal Motor Associations of Iron Accumulation in Parkinson’s Disease

    A. Martin-Bastida, N. Lao-Kaim, Y. Xing, C. Loane, A. Roussakis, S. Schwarz, N. Valle-Guzman, P. Mahlknecht, X. Li, G. Paul-Visse, H. Widner, M. Politis, T. Foltynie, R. Barker, D. Auer, P. Piccini (London, United Kingdom)

    Objective: To assess whether longitudinal changes in deep grey matter nuclei iron content are associated with declining motor function in Parkinson’s disease over a period…
  • 2017 International Congress

    Assessing Nigral Functional Connectivity in Parkinson’s Disease with Resting State Functional MRI

    A. Martin-Bastida, Y. Xing, S. Pietracupa, A. Roussakis, N. Lao-Kaim, W. Li, X. Li, P. Mahlknecht, S. Schwarz, T. Foltynie, D. Auer, P. Piccini (London, United Kingdom)

    Objective: To evaluate functional connectivity of SN with basal ganglia and motor cortex in Parkinson’s disease (PD) using resting state functional MRI (RS fMRI). Background:…
  • 2017 International Congress

    Clinical utility of visualization of Nigrosome-1 in patients with Parkinson’s disease

    A. Sunny, R. Naduthota, R. Botta, S. Varadharajan, J. Saini, R. Yadav, P. Pal (Bangalore, India)

    Objective: To determine the inter-rater reliability of Nigrosome-1 detection and its relation to asymmetry of clinical symptoms in Parkinson’s disease (PD).  Background: Detection of Nigrosome-1…
  • 2017 International Congress

    Volume analysis and localization of midbrain hyperechogenecities via TCS and MRI

    A. Plate, S.-A. Ahmadi, K. Boetzel (Munich, Germany)

    Objective: We are presenting follow-up results on our previous study for 3D volumetric measurements of SN hyper-echogenicities, to differentiate PD patients from healthy controls (HC).…
  • 2016 International Congress

    Gene expression analysis using the Parkinson’s disease map reveals early effects of alpha-synuclein on PD pathogenesis

    S. Gebel, A. Ashrafi, P. Garcia, M. Ostaszewski, P. Gawron, L. Vallar, N. Nicot, T. Kaoma, R. Balling, E. Glaab, M. Buttini (Esch-sur-Alzette, Luxembourg)

    Objective: The identification of early disease markers for Parkinson's disease (PD) is essential, since the disease is already in an advanced state when motor symptoms…
  • 2016 International Congress

    In vivo MRI detection of Parkinson’s disease associated degeneration in the lateral ventral tier of substantia nigra pars compacta

    D.E. Huddleston, J. Langley, J. Sedlacik, K. Boelmans, S.A. Factor, X. Hu (Atlanta, GA, USA)

    Objective: To test a novel multimodal MRI approach for in vivo assessment of the subregion of substantia nigra pars compacta (SNpc) most vulnerable to Parkinson's…
  • 2016 International Congress

    Identification of Usp8 as a toxicity modifying deubiquitinase for α-synuclein

    Z. Alexopoulou, J. Lang, R. Perrett, H.T. Kim, A.L. Goldberg, O. Ansorge, T.A. Fulga, G.K. Tofaris (Oxford, United Kingdom)

    Objective: To study whether ubiquitination in Lewy bodies is directly relevant to α-synuclein turnover and Parkinson's pathogenesis. Background: In Parkinson's disease, misfolded α-synuclein accumulates, often…
  • 2016 International Congress

    Substantia nigra hyperechogenicity in Mexican patients with Parkinson’s disease

    C.Y. Rodriguez-Garza, A. Anaya-Escamilla, R. Pinales-Razo, I. Estrada-Bellmann, C.R. Camara-Lemarroy (Monterrey, Mexico)

    Objective: To determine the prevalence of increased echogenicity in the substantia nigra in patients diagnosed with idiopathic Parkinson's disease at the University Hospital "Dr. José…
  • 2016 International Congress

    SOD1 aggregation: A pathological link between Parkinson’s disease and amyotrophic lateral sclerosis?

    B.G. Trist, K.M. Davies, S. Genoud, V. Smoothy, G.M. Halliday, S. Roudeau, A. Carmona, L. Perrin-Verdugier, R. Ortega, K.L. Double (Sydney, Australia)

    Objective: To characterize (1) a novel association between superoxide dismutase 1 (SOD1) aggregation and neuronal loss in the Parkinson's disease (PD) brain and (2) the…
  • « Previous Page
  • 1
  • …
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • Next Page »

Most Viewed Abstracts

  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • “Magic carpet for freezing of gait ” Evaluating a combination of patterned and pictographic visual cues.
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley